Bristol Myers Squibb (BMY) Total Debt (2009 - 2026)
Bristol Myers Squibb (BMY) reported Total Debt of $44.5 billion for Q1 2026, down 10.56% year-over-year from $49.7 billion in Q1 2025, and down 1.44% on a QoQ basis from $45.1 billion in Q4 2025.
Bristol Myers Squibb (BMY) has 18 years of Total Debt data on file, last reported at $44.5 billion in Q1 2026.
- Quarterly Total Debt fell 10.56% year-over-year to $44.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.5 billion (down 10.56% YoY) and the FY2025 annual result came in at $45.1 billion, down 9.14% from the prior year.
- Total Debt declined to $44.5 billion in Q1 2026 per BMY's latest filing, from $45.1 billion in the prior quarter.
- Across five years, Total Debt topped out at $55.7 billion in Q1 2024 and bottomed at $37.6 billion in Q3 2023.
- The 5-year median for Total Debt is $45.0 billion (2022), against an average of $44.9 billion.
- The widest annual swing landed in 2023, when Total Debt declined 15.88%; it then soared 47.18% in 2024.
- Tracing BMY's Total Debt over 5 years: stood at $39.3 billion in 2022, then rose by 1.15% to $39.8 billion in 2023, then rose by 24.83% to $49.6 billion in 2024, then dropped by 9.14% to $45.1 billion in 2025, then declined by 1.44% to $44.5 billion in 2026.
- Per Business Quant, the three latest BMY Total Debt figures stand at $44.5 billion (Q1 2026), $45.1 billion (Q4 2025), and $49.0 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 43.37 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 54.99 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 64.53 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 49.12 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 57.32 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 22.17 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 64.46 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 44.46 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 23.56 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.46 Bn |
| Dec 31, 2025 | 45.11 Bn |
| Sep 30, 2025 | 48.98 Bn |
| Jun 30, 2025 | 49.19 Bn |
| Mar 31, 2025 | 49.71 Bn |
| Dec 31, 2024 | 49.65 Bn |
| Sep 30, 2024 | 49.75 Bn |
| Jun 30, 2024 | 52.39 Bn |
| Mar 31, 2024 | 55.68 Bn |
| Dec 31, 2023 | 39.77 Bn |
| Sep 30, 2023 | 37.60 Bn |
| Jun 30, 2023 | 37.68 Bn |
| Mar 31, 2023 | 37.83 Bn |
| Dec 31, 2022 | 39.32 Bn |
| Sep 30, 2022 | 39.10 Bn |
| Jun 30, 2022 | 42.06 Bn |
| Mar 31, 2022 | 44.97 Bn |
| Dec 31, 2021 | 44.55 Bn |
| Sep 30, 2021 | 44.74 Bn |
| Jun 30, 2021 | 45.16 Bn |
| Mar 31, 2021 | 46.28 Bn |
| Dec 31, 2020 | 50.68 Bn |
| Sep 30, 2020 | 44.95 Bn |
| Jun 30, 2020 | 46.67 Bn |
| Mar 31, 2020 | 46.71 Bn |
| Dec 31, 2019 | 46.73 Bn |
| Sep 30, 2019 | 24.96 Bn |
| Jun 30, 2019 | 24.98 Bn |
| Mar 31, 2019 | 6.02 Bn |
| Dec 31, 2018 | 7.35 Bn |
| Sep 30, 2018 | 7.31 Bn |
| Jun 30, 2018 | 7.39 Bn |
| Mar 31, 2018 | 7.70 Bn |
| Dec 31, 2017 | 7.96 Bn |
| Sep 30, 2017 | 8.44 Bn |
| Jun 30, 2017 | 8.22 Bn |
| Mar 31, 2017 | 8.43 Bn |
| Dec 31, 2016 | 6.71 Bn |
| Sep 30, 2016 | 6.83 Bn |
| Jun 30, 2016 | 6.74 Bn |
| Mar 31, 2016 | 6.70 Bn |
| Dec 31, 2015 | 6.69 Bn |
| Sep 30, 2015 | 7.27 Bn |
| Jun 30, 2015 | 7.37 Bn |
| Mar 31, 2015 | 7.46 Bn |
| Dec 31, 2014 | 7.83 Bn |
| Sep 30, 2014 | 7.67 Bn |
| Jun 30, 2014 | 7.74 Bn |
| Mar 31, 2014 | 7.65 Bn |
| Dec 31, 2013 | 8.34 Bn |
| Sep 30, 2013 | 7.21 Bn |
| Jun 30, 2013 | 7.21 Bn |
| Mar 31, 2013 | 7.89 Bn |
| Dec 31, 2012 | 7.39 Bn |
| Sep 30, 2012 | 7.36 Bn |
| Jun 30, 2012 | 5.45 Bn |
| Mar 31, 2012 | 5.42 Bn |
| Dec 31, 2011 | 5.49 Bn |
| Sep 30, 2011 | 5.62 Bn |
| Jun 30, 2011 | 5.52 Bn |
| Mar 31, 2011 | 5.41 Bn |
| Dec 31, 2010 | 5.45 Bn |
| Dec 31, 2009 | 6.36 Bn |
| Sep 30, 2009 | 6.59 Bn |
| Jun 30, 2009 | 6.36 Bn |